The FDA announced it would give priority review to Eliquis, an anticlotting drug produced by Bristol-Myers Squibb and Pfizer, according to a Wall Street Journal report.
Uncategorized
Andrew C. Charles, MD, a professor of neurology and director of UCLA's Headache Research and Treatment Program, has been named the first holder of the Meyer and Renee Luskin Chair in Migraine and Headache Studies, according to a UCLA news…
A study found opioid prescriptions for chronic abdominal pain more than doubled in U.S. outpatient clinics from 1997-2008, according to an American Gastroenterological Association news release.
DSM, a global science-based company active in health, nutrition and materials, and AdeTherapeutics, a clinical-stage product development company located in Canada, signed a joint collaboration agreement to accelerate DSM's scar reduction and pain management product development strategy in neurosurgery, according…
Several medical device companies gathered at the North American Spine Society annual conference this past month to display new innovations for a variety of spinal procedures. Even through tough economic times, companies displayed an impressive array of innovation, which could…
Raleigh (N.C.) Plastic Surgery Center has announced it has received accreditation from the Accreditation Association for Ambulatory Health Care, according to a Raleigh Plastic Surgery Center news release.
Healthmark Industries Co., which develops products for the sterilization, decontamination, storage and security of surgical instruments and other medical devices and accessories, has announced the launch of its AccuPoint-HC system, designed to help reduce hospital-acquired infections, according to a news…
Michael McCracken, MD, announced the opening of McCracken Eye and Face Institute's new Boulder, Colo., location, according to a news release.
Medtronic CFO, Gary Ellis, said the company plans to cut $1.2 billion in operation costs as the company finishes a five-year, $1 billion plan that lowered its expenses by 25 percent, according to a MassDevice report.
BioMarin Pharmaceutical announced the FDA approved expansion of a manufacturing facility where the company makes several of its drugs and a key experimental drug, according to a San Francisco Chronicle report.
